Showing 6341-6350 of 7756 results for "".
- FDA Nod for Modifications to Soliton's Resonic Devicehttps://practicaldermatology.com/news/fda-nod-for-modifications-to-solitons-tattoo-removal-device/2460790/The U.S. Food and Drug Administration granted Soliton, Inc. 510(k) for modifications to its RESONIC device. The RESONIC device utilizes the RAP technology to deliver safe and effective tattoo removal and cellulite treatment and now includes an autoloading cartridge and an
- Natroba Now Approved for Scabies in Adults and Children as Young as Fourhttps://practicaldermatology.com/news/natroba-now-approved-for-scabies-in-adults-and-children-as-young-as-four/2460789/Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Dru
- UCB: Bimekizumab PDUFA Date Set for Octoberhttps://practicaldermatology.com/news/ucb-bimekizumab-pdufa-set-for-october/2460787/The FDA's Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is October 15, 2021, UCB has indicated. In a
- Skin Cancer Foundation Champions for Change Gala Goes Virtualhttps://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-goes-virtual/2460783/The Champions for Change Gala, the Skin Cancer Foundation’s signature fundraising event, be held virtually, Tuesday, May 11. Proceeds from the annual event support the organization’s educational campaigns, community programs, and research initiatives. The event will be
- Henry Ford Innovations, Google Cloud, and Miracle Software Systems to Fund Innovations Focused on Health Inequitieshttps://practicaldermatology.com/news/henry-ford-innovations-google-cloud-and-miracle-software-systems-to-fund-innovations-focused-on-health-inequities/2460782/Entrepreneurs with ideas for reducing health inequities through the use of digital technology could garner $75,000 in cash and in-kind support toward developing their digital solution at Henry Ford Health System.
- Sirnaomics Starts Phase 2b Study of STP705 for SCChttps://practicaldermatology.com/news/sirnaomics-inc-starts-phase-2b-study-of-stp705-for-scc/2460778/Sirnaomics, Inc. is initiating a Phase 2b study of STP705 for the treatment of squamous cell skin cancer. STP705 is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- Zoom Dysmorphia Fuels Boost in Cosmetic Consultshttps://practicaldermatology.com/news/zoom-dysmorphia-fuels-boost-in-cosmetic-consults/2460760/During the pandemic, there was a shift to remote work, and demand for video conferencing increased which sired a corresponding rise in the number of patients with negative self-perceptions seeking cosmetic consultations, a new survey shows. In a survey of more than 100 board-certified d